"The voice for cancer physicians and their patients in Massachusetts."

  • Home
  • Resources
  • FDA Approvals
  • FDA Approves abemaciclib (Verzeno) as initial therapy for HR-Positive, HER2-negative metastatic breast cancer

FDA Approves abemaciclib (Verzeno) as initial therapy for HR-Positive, HER2-negative metastatic breast cancer

27 Feb 2018 11:54 AM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration approved abermacicib (Verzeno; Eli Lilly) in combination with an aromatase inhibitor as initial endocrine-based therapy for postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. Read full press release. 

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software